{"id":"W2985405196","doi":"10.1056/nejmoa1908639","title":"Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":2116,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital; McGill University Health Centre","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute of General Medical Sciences; Vertex Pharmaceuticals","keywords":"Ivacaftor; Cystic fibrosis; Medicine; Cystic fibrosis transmembrane conductance regulator; Placebo; Internal medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01751070533230126,"score_gpt":0.2934128043266692,"score_spread":0.2759020989943679,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}